U.S. Household Products Stock News

NYSE:MDT
NYSE:MDTMedical Equipment

How Investors Are Reacting To Medtronic (MDT) Balancing Growth, Margin Pressure, And A Diabetes Spin-Off

In February 2026, Medtronic plc reported third-quarter fiscal 2026 results showing higher sales of US$9,017 million but lower net income of US$1,143 million year-on-year, reaffirmed full-year EPS guidance of US$5.62 to US$5.66, and received U.S. FDA clearance for its Stealth AXiS spine surgical system. These updates, alongside a US$381 million antitrust jury verdict against Medtronic and ongoing diabetes-business restructuring, highlight a company balancing innovation and legal, margin, and...
NYSE:B
NYSE:BMetals and Mining

Barrick Mining (B) Valuation Check After Name Change And Strong 1 Year Shareholder Return

Barrick Mining (B) has drawn fresh attention after its 2025 name change from Barrick Gold Corporation, shifting investor focus to how its broader mix of gold, copper, silver, and energy materials supports the current valuation. See our latest analysis for Barrick Mining. The latest US$49.22 share price comes after a 25.82% 90 day share price return and an 11.66% year to date share price return, while the 1 year total shareholder return of 175.10% suggests recent momentum has been strong...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals and Sanofi recently received U.S. FDA approval for Dupixent to treat allergic fungal rhinosinusitis (AFRS) in adults and children aged 6 and older with a history of sino-nasal surgery, following a Priority Review supported by a Phase 3 trial showing marked improvements in sinus disease and symptoms. This ninth U.S. approval for Dupixent broadens its role in type 2 inflammatory diseases and introduces the first medicine specifically approved for AFRS, potentially...
NYSE:PAGS
NYSE:PAGSDiversified Financial

A Look At PagSeguro Digital (PAGS) Valuation As Shares React To Earnings Anticipation

PagSeguro Digital stock moves ahead of earnings PagSeguro Digital (PAGS) recently declined 6.38%, underperforming broader market losses, as investors focus on the company’s upcoming March 4 earnings report and what it might reveal about business momentum. See our latest analysis for PagSeguro Digital. The recent 6.38% 1 day share price decline comes after a period of mixed momentum, with a 7.86% 90 day share price return and a 43.27% 1 year total shareholder return, contrasting with a much...
NasdaqGS:ICLR
NasdaqGS:ICLRLife Sciences

A Look At ICON (ICLR) Valuation After Revenue Overstatement And Delayed Results

ICON (NasdaqGS:ICLR) is in focus after uncovering a revenue overstatement of under 2% for 2023 and 2024, delaying its Q4 and full year 2025 results and drawing a federal securities investigation. See our latest analysis for ICON. ICON’s latest revenue overstatement and the resulting regulatory scrutiny come after a sharp reset in market expectations, with a 30 day share price return of 43.94% decline and a 1 year total shareholder return of 47.45% decline, even as the recent 7 day share price...
NYSE:REZI
NYSE:REZIBuilding

A Look At Resideo Technologies (REZI) Valuation As ADI Separation Plans Aim To Unlock Value

Resideo Technologies (REZI) is drawing attention after recent trading left the shares at a last close of US$34.60, with a mixed return profile over the past year and over multi-year periods. See our latest analysis for Resideo Technologies. Recent trading has been choppy, with a 1-day share price return of 5.77% and a 7-day share price return of 3.43% pulling back some of the gains from a 90-day share price return of 8.77%. At the same time, the 1-year total shareholder return of 77.44% and...
NYSE:EPR
NYSE:EPRSpecialized REITs

Assessing EPR Properties (EPR) Valuation After Its Recent Share Price Momentum

EPR Properties (EPR) has drawn fresh attention after a sustained run in its unit price, with the REIT now sitting near US$59. That move, alongside its value score, is prompting closer scrutiny. See our latest analysis for EPR Properties. At the current share price of US$59.03, EPR Properties has posted a 30 day share price return of 8.97% and a year to date share price return of 16.29%, while its 1 year total shareholder return of 25.65% and 3 year total shareholder return of 78.25% point to...
NYSE:VMC
NYSE:VMCBasic Materials

Vulcan Materials Investor Day Webcast To Test Premium Valuation And Outlook

Vulcan Materials (NYSE:VMC) has scheduled an Investor Day event for March 12, 2026. The company will webcast the event, featuring presentations from the CEO and senior management. Management plans to share its current business outlook, strategic priorities, and operational plans with investors. For you as an investor, this Investor Day is an opportunity to hear directly from Vulcan Materials' leadership about how they see the business today. The company’s share price stands at $310.79, with...
NYSE:MNR
NYSE:MNROil and Gas

A Look At Mach Natural Resources (MNR) Valuation As Higher Cash Distribution Signals Confidence

Dividend move puts Mach Natural Resources in focus Mach Natural Resources (MNR) drew the attention of income-focused investors after its board declared a fourth quarter 2025 cash distribution of $0.53 per common unit, payable on March 12, 2026. See our latest analysis for Mach Natural Resources. At a last close of $13.50, Mach Natural Resources has seen its short term momentum build, with a 30 day share price return of 18.11% and year to date share price return of 20.00%, even though the 1...
NasdaqGS:LBTY.A
NasdaqGS:LBTY.ATelecom

Liberty Global (LBTY.A) Valuation Check After 2025 Profit Swing And Recent Share Price Rebound

Liberty Global (LBTY.A) is back in focus after reporting full year 2025 results, with sales of US$4,878.5 million and a net loss of US$7,138.1 million, reversing from net income a year earlier. See our latest analysis for Liberty Global. Investors appear to be reassessing Liberty Global after the earnings release, with a 1-day share price return of 2.47% and a 7-day share price return of 18.00% on the way to a 1-year total shareholder return of 13.02%. This suggests recent momentum has picked...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

Is It Time To Revisit GitLab (GTLB) After The Sharp Share Price Pullback?

If you are wondering whether GitLab's current share price reflects its real worth, you are not alone. This article is all about unpacking what the numbers suggest about value. GitLab shares last closed at US$24.03, after returns of an 18.7% decline over 7 days, a 33.9% decline over 30 days, a 33.6% decline year to date, and a 61.4% decline over the past year, with a 45.0% decline over 3 years. Recent coverage around GitLab has focused on its position within the software sector and how...
NYSE:ABBV
NYSE:ABBVBiotechs

The Bull Case For AbbVie (ABBV) Could Change Following Its New AI-Driven US Manufacturing And CLL Win

In recent days, AbbVie announced a US$380 million plan to build two AI-enabled active pharmaceutical ingredient facilities in North Chicago and secured US FDA approval for an all-oral, fixed-duration VENCLEXTA plus acalabrutinib regimen for previously untreated chronic lymphocytic leukemia patients. Together, these moves highlight AbbVie’s push to deepen its oncology footprint while scaling future neuroscience and obesity drug production within its US manufacturing base. We’ll now examine...
NasdaqGS:GSAT
NasdaqGS:GSATTelecom

How Investors Are Reacting To Globalstar (GSAT) Joining Virewirx’s US$1.9 Million 5G System Contract

Virewirx previously announced a US$1.9 million Phase II contract to develop an advanced 5G system, naming Globalstar as a key technology collaborator, while Globalstar also scheduled its fourth-quarter 2025 earnings release for February 27 before the market opened. This pairing of a specialized 5G collaboration with ongoing satellite and network investments highlights how Globalstar is pushing deeper into complex hybrid connectivity solutions. We’ll now examine how Globalstar’s role in...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

Is BioCryst Pharmaceuticals (BCRX) Offering Long-Term Value After Recent Share Price Swings

If you are wondering whether BioCryst Pharmaceuticals is attractively priced at its recent share price of US$7.58, you are not alone. This article will focus on what that number might really represent for long term investors. The stock has recently shown mixed momentum, with a 12.1% move over the past 7 days and 11.6% over 30 days, while the 1 year return sits at a decline of 8.6% and the 5 year return at a decline of 36.7%. These moves come against a backdrop of ongoing market attention on...
NasdaqGS:GTX
NasdaqGS:GTXAuto Components

Garrett Motion Expands Beyond Turbochargers With Zero Emission And Industrial Wins

Garrett Motion (NasdaqGS:GTX) announced new partnerships and product awards in zero emission mobility and industrial applications. The company secured a major serial award for its oil free centrifugal compressor with Cling for electric commercial vehicles in China. Garrett also launched the commercial debut of its MEG turbocharger with Weichai for marine and power generation uses. Garrett Motion, trading at $19.28, has seen its share price move 10.9% higher year to date and 103.3% over the...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Is Costco (COST) Still Attractive After Near Four Figure Share Price And Mixed Returns

If you are wondering whether Costco Wholesale's near four-figure share price still offers value, you are not alone. This article is designed to help you frame that question clearly. The stock last closed at US$986.02, with returns of a 3.2% decline over the past 7 days, 0.3% over 30 days, 15.4% year to date, a 4.3% decline over 1 year, 110.9% over 3 years and 213.9% over 5 years. Recent coverage has focused on Costco's consistent membership model, its large-scale warehouse footprint and its...
NYSE:AMT
NYSE:AMTSpecialized REITs

American Tower Insider Sales And Buyback Put Capital Decisions In Focus

American Tower (NYSE:AMT) recently completed a $365 million share buyback program. The company's CFO executed significant insider selling around the same period, drawing extra attention to management's actions. American Tower appointed a new chief accounting officer, marking a meaningful change in its finance leadership team. American Tower, trading at $190.05 at last close, is in the spotlight as investors weigh these moves together rather than in isolation. The stock is up 6.3% over the...
NYSE:ALB
NYSE:ALBChemicals

Albemarle (ALB) Valuation Check As Lithium Recovery Hopes And Cost Cuts Follow Plant Idle Decision

Albemarle (ALB) is back in focus after management moved to idle its Kemerton lithium hydroxide plant in Western Australia, while guiding to flat 2026 volumes and aiming for higher profitability as lithium prices recover. See our latest analysis for Albemarle. The Kemerton announcement and 2026 guidance landed after a period of sharp share price moves, with Albemarle up 5.40% on a 1 day share price return and 41.72% over 90 days. The 1 year total shareholder return of 123.63% contrasts with a...
NYSE:HCA
NYSE:HCAHealthcare

Will AI Optimism and New Capacity Expansion Shift HCA Healthcare's (HCA) Risk‑Reward Narrative?

HCA Healthcare recently featured at the ViVE 2026 conference in Los Angeles while expanding its footprint with new facilities in Florida, Texas, and Utah and holding weekly “Talent Thursdays” hiring events ahead of the HCA Florida Gainesville Hospital opening in May 2026. Together with broadened analyst optimism around artificial intelligence and potential Medicaid supplemental payment updates, these moves highlight how HCA is leaning into technology and physical capacity expansion to...
NYSE:DK
NYSE:DKOil and Gas

A Look At Delek US Holdings (DK) Valuation After Recent Annual Loss And Revenue Update

Delek US Holdings (DK) has been drawing attention after reporting annual revenue of US$10.67b alongside a net loss of US$541.2m. This combination is putting both its refining operations and valuation under closer investor scrutiny. See our latest analysis for Delek US Holdings. The latest results land as Delek US Holdings’ share price sits at US$33.25, with a 17.82% 1 month share price return but a 13.05% 3 month share price decline. The 1 year total shareholder return of 113.50% points to...
NasdaqCM:QMMM
NasdaqCM:QMMMMedia

Assessing QMMM Holdings (QMMM) Valuation After Sharp Share Price Momentum

What recent returns say about QMMM Holdings (QMMM) QMMM Holdings (QMMM) has attracted attention after a 19.4% one day move, a return of 19.4% over the past 3 months, and a year to date gain of 87.44%. See our latest analysis for QMMM Holdings. That surge in the 1 day share price return and the latest share price of $119.4 comes on top of a 90 day share price return of 19.4% and a very large year to date share price gain. The 1 year total shareholder return is also very large, suggesting...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck Reorganizes Human Health To Shape Life After Keytruda

Merck (NYSE:MRK) is restructuring its Human Health division into two units: Oncology and Specialty, Pharma & Infectious Diseases. The company has announced new executive appointments to lead each unit as part of this reorganization. The move is intended to sharpen focus on cancer care and the broader portfolio ahead of Keytruda patent expiration. With a current share price of $123.82, Merck comes into this reorganization after a strong run, with the stock up 14.5% over the past 30 days and...
NYSE:EW
NYSE:EWMedical Equipment

Edwards Lifesciences Expands Atrial Fibrillation Reach With 2026 Product Launch

Edwards Lifesciences, ticker NYSE:EW, plans to launch new left atrial appendage closure products in 2026. The products will build on the company’s existing surgical franchise to enter a growing treatment segment for atrial fibrillation patients. The move broadens Edwards Lifesciences’ portfolio beyond its core offerings in structural heart therapies. Edwards Lifesciences, trading at $82.44, is preparing to extend its reach with new left atrial appendage closure devices that sit alongside...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

TTM Technologies (TTMI) Is Up 16.4% After Earnings Beat, Outlook Hike And Tariff Relief - Has The Bull Case Changed?

In recent weeks, TTM Technologies reported an exceptionally strong fourth quarter with 19% year‑over‑year sales growth, raised its outlook, and gained relief from the U.S. Supreme Court’s decision to strike down global tariffs that had pressured its costs. At the same time, TTM has been highlighted as a key supplier for AI‑driven data center buildouts and defense programs, attracting fresh institutional interest from Metavasi Capital and reinforcing its role at the center of high‑reliability...